Nigel Moore, a senior wealth manager at Pilling & Co has been quoted in citywire.co.uk. Read the full article at:
‘The top 10 holdings now account for over 60% of the fund with significant biotech and healthcare exposure. I am concerned about the concentration effect. The long tail of 79 holdings account for the balance of the portfolio will be less material to returns moving forward,’ he said.
Given the risks associated with investing in the underlying companies, as well as the potential rewards, he would like less stocks to be held in the portfolio and a ‘tangible timeframe for exit’ outlined. He has held the trust since IPO for clients with a growth mandate.
‘We are now approaching the three-year anniversary with many investors in negative territory. How much more patient can investors be?’ he asked.